Skip to main content
Clinical Trials/NCT06192446
NCT06192446
Recruiting
Not Applicable

Factors Influencing Adherence to Adjuvant Endocrine Therapy in Women With Early Breast Cancer in Croatia

University of Zagreb1 site in 1 country1,000 target enrollmentSeptember 20, 2021

Overview

Phase
Not Applicable
Intervention
Survey using a questionnaire.
Conditions
Adherence, Treatment
Sponsor
University of Zagreb
Enrollment
1000
Locations
1
Primary Endpoint
Patient adherence to adjuvant endocrine therapy assessment: Measurement of the level of adherence to adjuvant endocrine therapy
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Breast cancer is the most common type of cancer and the leading cause of cancer death in women. Adjuvant endocrine therapy (AET) reduces the risk of disease recurrence and mortality in women with hormone-dependent breast cancer. This cross-sectional study aims to investigate adherence to AET and identify factors associated with adherence in the Republic of Croatia. The level of adherence, beliefs about medicines, and quality of life with AET will be investigated with validated instruments in the form of an anonymous survey. Given the available data on suboptimal adherence to AET in Europe and globally, it is clear that there is a need for investigating adherence in Croatia which hasn't been done so far. Each country, population, and health system has its own characteristics, and understanding the experience of using AET and identifying associated psychosocial factors could help in developing specific interventions supporting women and improving AET adherence.

Registry
clinicaltrials.gov
Start Date
September 20, 2021
End Date
September 20, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Iva Mucalo

Associate professor at the Center for Applied Pharmacy.

University of Zagreb

Eligibility Criteria

Inclusion Criteria

  • women older than 18 years of age
  • clinical diagnosis of hormone receptor positive early breast cancer stages 0-III according to the American Joint Committee on Cancer (AJCC) classification
  • prescribed with adjuvant endocrine therapy for more than 3 months

Exclusion Criteria

  • advanced metastatic breast cancer, stage IV according to the American Joint Committee on Cancer (AJCC) classification
  • other life-threatening illnesses
  • mental disorders
  • behavioral disorders caused by the use of psychoactive substances
  • behavioral syndromes related to physiological disorders and physical factors
  • cognitive impairment
  • organic and symptomatic mental disorder
  • schizophrenia
  • disorders similar to schizophrenia
  • delusional disorders

Arms & Interventions

Women with hormone-sensitive early breast cancer

Women older than 18 years of age who have suffered from hormonally dependent breast cancer stages 0-III (from "in situ" to locally advanced breast cancer) according to the American Joint Committee on Cancer (AJCC) classification and have been undergoing adjuvant endocrine therapy for more than 3 months.

Intervention: Survey using a questionnaire.

Outcomes

Primary Outcomes

Patient adherence to adjuvant endocrine therapy assessment: Measurement of the level of adherence to adjuvant endocrine therapy

Time Frame: Day 1.

The overall aim of the study is to determine the proportion of women adherent to oral adjuvant endocrine therapy (AEL) after the diagnosis of breast cancer in Croatia, as well as to investigate the association between AEL adherence, medication beliefs, quality of life, sociodemographic, and clinical factors.

Secondary Outcomes

  • Prevalence of Treatment-Emergent Adverse Events as assessed by FACT-ES(Day 1.)
  • Beliefs About Medicines(Day 1.)

Study Sites (1)

Loading locations...

Similar Trials